Table 2.

Most common regimens used across index and subsequent LOT.

LOT	Number of unique regimens	Most common regimens,a (%)
Index LOT	91	Kd (14.1), CPd (14.1), Pd (11.7)
1st Subsequent LOT (n = 152)	78	blmf (10.5), PCd (6.6)
2nd Subsequent LOT (n = 74)	47	blmf (18.9), KCd (5.4), Kd (5.4)
3rd Subsequent LOT (n = 42)	30	blmf (19.0), IsaPd (11.9), DKd (4.8)
≥4th Subsequent LOT (n = 17)	34	blmf (17.6)

blmf belantamab mafodotin, PCd pomalidomide, cyclophosphamide, and dexamethasone, DKd daratumumab, carfilzomib, and dexamethasone, IsaPd isatuximab, pomalidomide, and dexamethasone, KCd carfilzomib, cyclophosphamide, and dexamethasone, Kd carfilzomib and dexamethasone, LOT line of therapy, Pd pomalidomide and dexamethasone.

^aPatients can be counted in >1 regimen per LOT.